|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.30 - 2.35|
|52 Week Range||1.55 - 5.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The US$101.80M market-cap company announcedRead More...
The Redwood City, California-based company said it had a loss of 20 cents per share. The drugmaker posted revenue of $740,000 in the period. For the year, the company reported that its loss widened to ...
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
Examining AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
The Redwood City, California-based company said it had a loss of 28 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Today, I will be analyzing AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its shareRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AcelRx Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACRX-US. Comparing the performance and risk of AcelRx Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia. There were more than 33,000 deaths in the United States in 2015 related to the abuse of the family of heavy-duty painkillers, and the resulting outcry has made the FDA extremely cautious about issuing new approvals. The FDA last month rejected another opioid painkiller made by Intellipharmaceutics International Inc , asking for more proof of the drug's ability to prevent abuse.
U.S. health regulators did not approve AcelRx Pharmaceuticals Inc's drug Dsuvia in its present form for the management of acute pain in trauma and ambulatory settings, the company said on Thursday. The ...
AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.
If you are a shareholder in AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...